Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire November 12, 2025 Expect decision regarding the advancement of an AB oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in […]
Ocular Therapeutix(TM) to Participate in November and December Investor Conferences GlobeNewswire November 12, 2025 BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in November and December, 2025. Jefferies Global Healthcare Conference
Sanara MedTech Inc. Reports Third Quarter 2025 Financial Results (Unaudited) GlobeNewswire November 12, 2025 Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update GlobeNewswire November 12, 2025 – Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision – – Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for
Dispatch Energy Acquires Green Lantern Solar (GLS), Extending its Distributed Generation Footprint Across Nine States The acquisition includes 64 projects, totalling 208.9 MWdc, which strengthens Dispatch's position in the solar generation market and expands Dispatch's operations and maintenance services GlobeNewswire November 12, 2025 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Dispatch Energy LLC (“Dispatch”),
Bunzl Canada Earns 2025 Great Place to Work(R) Certification Employee Trust Index affirms commitment to a thriving, inclusive workplace culture GlobeNewswire November 12, 2025 Bunzl Canada's annual Delivery & Warehouse Appreciation Week recognizes the dedication of drivers and warehouse teams, fostering a culture of respect, pride, and trust that supports its Great Place To Work(R)
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference GlobeNewswire November 12, 2025 BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Jefferies Global Healthcare
SEED Therapeutics Receives IND Clearance from China's NMPA for ST-01156 China Sites to Join Upcoming Global Expansion Study Evaluating RBM39-Dependent Cancers GlobeNewswire November 12, 2025 KING OF PRUSSIA, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) — SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs GlobeNewswire November 12, 2025 NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its strategic investment in
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 12, 2025 Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA(TM) Phase 1 heme trial to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition